Vetter starts operations in its center for visual inspection and logistics
Site enlargement enables increased capacity for state-of-the-art quality control and storage.
Vetter has begun operations in its expanded Visual Inspection and Logics Center located in Ravensburg. The enlargement, in which the company invested approximately 100 million euro ($107 million), bundles capacity for final product inspection and logistics in one cutting-edge site. By finalizing the second construction stage of the site that was initially put into operation 5 years ago, the CDMO now offers more than double the capacity for state-of-the-art quality control, cold-storage and room-temperature storage. Given the increasing industry-specific requirements emanating from customer and regulatory side, the company now provides even more efficient and flexible supply chain processes.
The expanded Center, referred to as Ravensburg Vetter West, is located on approximately 50,000 m2 (538,000 sq ft) of floor space and offers a 35,000 pallet warehouse capacity for storing pharmaceuticals in refrigeration or room temperature conditions. The capacities for chest freezers, incubation chambers, and constant climate chambers have also been increased, as have the visual inspection capacities of filled units which can be realized in either manual or automatic mode. This allows Vetter to react with greater flexibility to individual market and customer needs. The center also contains a support materials warehouse with corresponding safety installations as well as a new packaging-check laboratory and the company’s central archive. Additionally, the number of office workspaces were increased. By the end of 2017, the CDMO will relinquish its existing Holbeinstrasse site for visual inspection and logistics. Its employees and departments will gradually be relocated to Ravensburg Vetter West, resulting in a working staff of approximately 800 employees.
“The requirements regarding final product inspection as well as transportation and storage of (bio-)pharmaceutical materials are ever-increasing,” said Vetter Managing Director Thomas Otto. “Concentrating our supply chain processes in one site enables bundled resources for even more efficient and highly-secured logistic and quality control procedures.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance